Loading page…

Report overview

The report describes FY 2021-22 sales of ₹3,230 crore and Wockhardt's international and research-driven pharmaceutical performance. It highlights six New Chemical Entities under development with QIDP status and the company's collaboration with Serum Life Sciences UK to expand global vaccine manufacturing. The report also emphasizes community programmes and reports a global talent base of approximately 4,000 associates.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021-2022
Period: 1 April 2021 – 31 March 2022
Publication date: 30 May 2022
Language
Pages
File size

Standards & Assurance

Assurance

Level
Standard
Scope
Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services